CFM
VRTX icon

Catalyst Funds Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Catalyst Funds Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.48M Buy
7,001
+6,036
+625% +$2.68M 0.19% 129
2026
Q1 		$431K Buy
965
+405
+72% +$189K 0.07% 275
2025
Q4 		$254K Buy
+560
New +$241K 0.06% 255
2024
Q4 		– Sell
-400
Closed -$186K – 1260
2024
Q3 		$186K Buy
+400
New +$192K 0.04% 308

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Catalyst Funds Management's VRTX Position: Q2 2026 in Review

Catalyst Funds Management increased its Vertex Pharmaceuticals (VRTX) stake by 625% in Q2 2026, buying an estimated $2.68M and bringing the position to 7,001 shares worth $3.48M. The position accounts for 0.19% of the portfolio, ranked #129.

Catalyst Funds Management first reported a position in VRTX in Q3 2024 and has held it in 4 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Catalyst Funds Management held 7,001 shares of Vertex Pharmaceuticals worth $3.48M as of Q2 2026.
  • Catalyst Funds Management bought 6,036 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.68M.
  • Vertex Pharmaceuticals made up 0.19% of Catalyst Funds Management's portfolio in Q2 2026, its #129 holding.
  • Catalyst Funds Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.